When does Opdivo’s (nivolumab) patent protection end?
Opdivo’s patent protection timeline depends on which patent rights you mean (for example, primary drug patents covering composition or formulation, and secondary patents covering specific uses or manufacturing). The exact end date isn’t set by the brand name alone; it varies by patent and by jurisdiction.
Is there a single “end date” for Opdivo patents?
No. Patent protection is granted and expires patent-by-patent. Some patents can expire earlier, while others remain in force longer, so “patent protection ends” can refer to:
- the earliest relevant patent expiration blocking generic or biosimilar entry in a country, or
- the last-expiring patent that still provides enforceable exclusivity in that jurisdiction.
Does patent protection line up with market exclusivity dates?
Not necessarily. Even after a patent expires, other forms of protection (such as regulatory exclusivity rules or additional patents) can still affect when a lower-cost competitor can enter. The timeline can therefore differ between:
- patent expiration (legal right in court), and
- regulatory exclusivity / market authorization periods (administrative and regulatory rules).
What I need to give you an exact date
If you tell me the country (US, EU, UK, etc.) and whether you mean the earliest blocking patent expiration or the last one, I can map the likely expiration window to the relevant patent set.
Quick clarification to answer precisely
Which market do you care about—United States or Europe (or a specific country)? And do you want the earliest end date for “patent protection,” or the last patent that could still delay biosimilar entry?